Eli Lilly profit drops sharply on Zyprexa generics
(Reuters) - Eli Lilly & Co's (LLY.N) quarterly profit dropped 27 percent after its top-selling Zyprexa schizophrenia treatment lost U.S. patent protection and saw competition from generic rivals.
The drugmaker backed its 2012 outlook that calls for a steep drop in profit this year due largely to the Zyprexa loss. It said an independent safety committee recommended continuing two late-stage clinical trials for its closely watched experimental Alzheimer's treatment.
Lilly's fourth-quarter net income fell to $858.2 million, or 77 cents per share, from $1.17 billion, or $1.05 per share, a year ago.
Excluding items, earnings of 87 cents per share were 6 cents ahead of the average estimate of analysts, according to Thomson Reuters I/B/E/S.
- Investigators look for motive in Malaysia plane disappearance |
- Malaysian PM says lost airliner was diverted deliberately |
- Police make third arrest in murder of Colorado socialite
- Democrats seek ways to limit Obamacare fallout after Florida defeat
- Indian Ocean poses daunting challenge in search for missing Malaysia plane